| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | 2025/Q3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 270.996.711 $ | +122.024.340 $ | +25,6 % | 9 | 164.402.957 $ | +55.659.346 $ | +45,7 % | 7 | 108.743.611 $ | +28.014.698 $ | +32,5 % | 6 | ||||
| ALUMIS INC. | ALMS | → 0 | Neutral | 129.910.800 $ | +73.504.364 $ | +130,3 % | 1 | 56.406.436 $ | +33.346.837 $ | +144,6 % | 1 | 23.059.599 $ | +5.721.555 $ | +33,0 % | 1 |
| CG Oncology, Inc. | CGON | → 0 | Neutral | 67.954.104 $ | +26.265.948 $ | +63,0 % | 1 | 41.688.156 $ | +1.245.022 $ | +3,1 % | 1 | 40.443.134 $ | +14.337.834 $ | +54,9 % | 1 |
| Disc Medicine, Inc. | IRON | → 0 | Schwach | 23.917.972 $ | +168.903 $ | +0,7 % | 1 | 23.749.069 $ | +3.986.589 $ | +20,2 % | 1 | 19.762.480 $ | +3.923.786 $ | +24,8 % | 1 |
| Hims & Hers Health, Inc. | HIMS | → 0 | Neutral | 15.324.015 $ | +6.454.802 $ | +72,8 % | 1 | 8.869.213 $ | -6.623.912 $ | -42,8 % | 1 | 15.493.125 $ | +1.876.548 $ | +13,8 % | 1 |
| Natera, Inc. | NTRA | → 0 | Neutral | 15.430.586 $ | +15.430.586 $ | 1 | |||||||||
| Lyell Immunopharma, Inc. | LYEL | → 0 | Neutral | 9.570.185 $ | -5.114.276 $ | -34,8 % | 1 | 14.684.461 $ | +6.936.714 $ | +89,5 % | 1 | 7.747.747 $ | +4.152.943 $ | +115,5 % | 1 |
| Eikon Therapeutics, Inc. | EIKN | → 0 | Schwach | 13.954.840 $ | +13.954.840 $ | 1 | |||||||||
| Pharvaris N.V. | PHVS | → 0 | Neutral | 5.484.031 $ | +5.484.031 $ | 1 | |||||||||
| Nurix Therapeutics, Inc. | NRIX | → 0 | Neutral | 4.107.500 $ | +4.107.500 $ | 1 | |||||||||
| Maze Therapeutics, Inc. | MAZE | → 0 | Sehr schwach | 773.264 $ | -2.801.772 $ | -78,4 % | 1 | 3.575.036 $ | +1.337.510 $ | +59,8 % | 1 | 2.237.526 $ | -1.997.968 $ | -47,2 % | 1 |
| 270.996.711 $ | +122.024.340 $ | +25,6 % | 9 | 164.402.957 $ | +55.659.346 $ | +45,7 % | 7 | 108.743.611 $ | +28.014.698 $ | +32,5 % | 6 | ||||